Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany
European Journal of Neurology · 2026-04 · 33 (4)
DOI: 10.1111/ene.70596 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 15.04.2026. Verfasst von Lea Gerischer und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology With Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-…. Hauptthemen laut MEDLINE: Myasthenia Gravis, Antibodies, Monoclonal, Humanized, Complement Inactivating Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Generalized myasthenia gravis (gMG) may progress to life‐threatening myasthenic crises (MC) requiring mechanical ventilation. Standard therapy includes intravenous immunoglobulins (IVIg), plasmapheresis (PLEX), immunoadsorption (IA), and high‐dose corticosteroids. This study aimed to evaluate the real‐world effectiveness of complement‐inhibitors (C5‐I) in patients refractory to the standard treatment of MC (termed therapy‐refractory MC).
Methods
This multicentre, retrospective study included patients with acetylcholine‐receptor‐antibody positive (AChR‐ab+) gMG experiencing MC or severe exacerbations (MGFA IVb/V) treated with eculizumab or ravulizumab in the intensive or intermediate care unit (ICU/IMC). The primary outcome was the proportion of patients discharged from ICU/IMC within six weeks after C5‐I initiation (German Clinical Trials Registry; DRKS00032104).
Results
Among 17 identified cases, seven had thymoma‐associated MG (TAMG) and 10 had late‐onset MG; median age was 77 years. Five patients required non‐invasive and 12 invasive ventilation; nine underwent tracheotomy. Therapies included IVIg, PLEX, IA, and corticosteroids. Rituximab was added in two cases. Twelve patients received eculizumab and five ravulizumab. Median hospitalization before C5‐I initiation was 32 days (IQR 22–50) and median ICU‐stay was 17 days (IQR 4.5–35) thereafter. Fourteen patients (82%) reached the primary outcome. Two patients died due to bacterial sepsis; no meningococcal infection was observed.
Conclusion
In MC or severe exacerbations insufficiently responsive to standard treatment with IVIg and PLEX/IA, add‐on C5‐I therapy may represent an effective therapeutic approach. Importantly, TAMG, a subtype typically excluded from interventional trials yet often requiring more intensive therapy, also demonstrated clinical improvement. These findings warrant further systematic evaluation of C5‐I as adjunctive therapy for AChR‐ab+ therapy‐refractory MC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology With Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Neuroscience Clinical Research Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Digital Health Center, Berlin, Germany.
- Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.
- Department of Neurology, Knappschaft Kliniken Dortmund, Dortmund, Germany.
ORCID-Profile: Lea Gerischer, Maike Stein, Alice Schneider, Stefanie Glaubitz, Jana Zschüntzsch, Ulrich Hofstadt-van Oy, Charlotte Schubert, Christoph Heesen, Tim Hagenacker, Tobias Ruck, Paolo Doksani, Carla Dusemund, Meret Herdick, Julia Herzig-Nichtweiß, Philipp Mergenthaler, Frauke Stascheit, Lisa Schwarz, Sarah Hoffmann, Andreas Meisel, Sophie Lehnerer
Zitieren
APA
Gerischer, L., Stein, M., Schneider, A., Tangen, H., Loris, J., Glaubitz, S., Zschüntzsch, J., Oy, U. H., Schubert, C., Heesen, C., Schlag, M., Hagenacker, T., Oeztuerk, M., Ruck, T., Doksani, P., Dusemund, C., Herdick, M., Herzig-Nichtweiß, J., Mergenthaler, P., …, & Lehnerer, S. (2026). Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany. European Journal of Neurology, 33(4). https://doi.org/10.1111/ene.70596
Vancouver
Gerischer L, Stein M, Schneider A, Tangen H, Loris J, Glaubitz S, et al. Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany. European Journal of Neurology. 2026;33(4). doi:10.1111/ene.70596
BibTeX
@article{Gerischer2026,
author = {Gerischer, Lea and Stein, Maike and Schneider, Alice and Tangen, Hanna and Loris, Johanna and Glaubitz, Stefanie and Zschüntzsch, Jana and Oy, Ulrich Hofstadt-van and Schubert, Charlotte and Heesen, Christoph and Schlag, Melina and Hagenacker, Tim and Oeztuerk, Menekse and Ruck, Tobias and Doksani, Paolo and Dusemund, Carla and Herdick, Meret and Herzig-Nichtweiß, Julia and Mergenthaler, Philipp and Stascheit, Frauke and Suboh, Amani and Schwarz, Lisa and Hoffmann, Sarah and Meisel, Andreas and Lehnerer, Sophie},
title = {Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {4},
doi = {10.1111/ene.70596}
}
EUVIMED